Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Journal of Pathology. Clinical Research|July 19, 2025
Pathogenesis of peritoneal high-grade serous carcinoma after risk-reducing surgery: a systematic reviewTamar A Gootzen, Anouk B Bouwmeester, Joanne A de Hullu, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|June 16, 2026
Recommendations for the use of CanRisk for tubo-ovarian cancer risk estimation: a focus group and Research ANd Development-modified Delphi-based studyTamar A Gootzen, Jolijn Schauwaert, Miranda P Steenbeek, et al.
American Journal of Obstetrics and Gynecology|November 3, 2025
Salpingectomy in individuals at high risk for tubo-ovarian cancer: consensus and precautionRoni Nitecki Wilke, Kathryn P Pennington, Tamar A Gootzen, et al.
O&G Open|September 26, 2025
Patients' Perspectives on Opportunistic Salpingectomy at the Time of Nongynecologic SurgeryCharlotte Fisch, Jolijn Schauwaert, Tamar A Gootzen, et al.
American Journal of Obstetrics and Gynecology|June 20, 2026
International Trends in Concurrent Hysterectomy at Risk-Reducing Surgery in BRCA1/2 pathogenic variant carriers: A mixed-methods studyTamar A Gootzen, Barbara M Norquist, Roni Nitecki Wilke, et al.
Cancers|July 13, 2024
Online Provision of <i>BRCA1</i> and <i>BRCA2</i> Health Information: A Search Engine Driven Systematic Web-Based AnalysisTamar A Gootzen, Ashwin Kalra, Katrina Sarig, et al.
American Journal of Obstetrics and Gynecology|June 18, 2025
Impact of breast cancer history on decision-making for ovarian cancer risk-reducing surgery in the TUBA-WISP-II studyTamar A Gootzen, Miranda P Steenbeek, Marleen M H J van Gelder, et al.
Journal of the National Cancer Institute|April 9, 2026
Menopause-related quality of life five years after salpingectomy with delayed oophorectomy versus Salpingo-OophorectomyTamar A Gootzen, Rosella Pmg Hermens, Marleen Mhj van Gelder, et al.
Maturitas|February 23, 2026
Development of cardiovascular risk factors in women with a BRCA1/2 pathogenic variant within five years after tubo-ovarian cancer risk reduction in the TUBA studyTamar A Gootzen, Marleen M H J van Gelder, Rosella P M G Hermens, et al.
Pageof 1